Journal article
Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine
Pharmacopsychiatry, Vol.47(4-5), pp.141-144
07/2014
DOI: 10.1055/s-0034-1377042
PMCID: PMC4174587
PMID: 24955551
Abstract
Deficiencies in both vitamin B12 and folate have been associated with depression. Recently, higher baseline vitamin B12 levels were observed in individuals with bipolar depression who responded to the antidepressant ketamine at 7 days post-infusion. This study sought to -replicate this result by correlating peripheral vitamin levels with ketamine's antidepressant efficacy in bipolar depression and major depressive disorder (MDD).
Baseline vitamin B12 and folate levels were obtained in 49 inpatients with treatment-resistant MDD and 34 inpatients with treatment-resistant bipolar depression currently experiencing a major depressive episode. All subjects received a single intravenous ketamine infusion. Post-hoc Pearson correlations were performed between baseline vitamin B12 and folate levels, as well as antidepressant response assessed by percent change in Hamilton Depression Rating Scale (HDRS) scores from baseline to 230 min, 1 day, and 7 days post-infusion.
No significant correlation was observed between baseline vitamin B12 or folate and percent change in HDRS for any of the 3 time points in either MDD or bipolar depression.
Ketamine's antidepressant efficacy may occur independently of baseline peripheral vitamin levels.
Details
- Title: Subtitle
- Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine
- Creators
- N B Lundin - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDM J Niciu - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDD A Luckenbaugh - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDD F Ionescu - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDE M Richards - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDJ L Vande Voort - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDN E Brutsche - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDR Machado-Vieira - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MDC A Zarate Jr - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Intramural Research Program, Bethesda, MD
- Resource Type
- Journal article
- Publication Details
- Pharmacopsychiatry, Vol.47(4-5), pp.141-144
- DOI
- 10.1055/s-0034-1377042
- PMID
- 24955551
- PMCID
- PMC4174587
- NLM abbreviation
- Pharmacopsychiatry
- ISSN
- 0176-3679
- eISSN
- 1439-0795
- Publisher
- Germany
- Grant note
- ZIA MH002857-09 / Intramural NIH HHS
- Language
- English
- Date published
- 07/2014
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984003478502771
Metrics
86 Record Views